Health‐related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26536
Abstract: In the phase 3 ANDROMEDA trial, patients treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone (D‐VCd) had significantly higher rates of organ and hematologic response compared with patients who received VCd alone. Here, we present patient‐reported… read more here.
Keywords: cyclophosphamide dexamethasone; vcd group; group; related quality ... See more keywords